Current Pharmacologic Management in Selected Neuromuscular Diseases

Andrew J. Skalsky, Bjorn Oskarsson, Jay J. Han, David Richman

Research output: Contribution to journalReview articlepeer-review


For generations, the neuromuscular disorder care community has focused on establishing the correct diagnosis and providing supportive care. As the pathophysiology and genetics of these conditions became better understood, novel treatments targeting the disease mechanism were developed. This has led to some significant disease-modifying and supportive treatments for several neuromuscular disorders. The current treatments for amyotrophic lateral sclerosis (ALS), neuromuscular junction disorders, inflammatory myopathies, and myotonia are reviewed. Additionally, investigational treatments for ALS, Duchenne muscular dystrophy, and spinal muscular atrophy are discussed.

Original languageEnglish (US)
Pages (from-to)801-820
Number of pages20
JournalPhysical Medicine and Rehabilitation Clinics of North America
Issue number4
StatePublished - Nov 1 2012


  • Amyotrophic lateral sclerosis
  • Duchenne muscular dystrophy
  • Inflammatory myopathy
  • Myasthenia gravis
  • Myotonia
  • Spinal muscular atrophy

ASJC Scopus subject areas

  • Physical Therapy, Sports Therapy and Rehabilitation
  • Rehabilitation


Dive into the research topics of 'Current Pharmacologic Management in Selected Neuromuscular Diseases'. Together they form a unique fingerprint.

Cite this